ESMO-话题@MedSci

#ESMO#

214篇内容 | 5258人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1280955, encodeId=d6c11280955f9, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2018 ESMO临床实践指南：非上皮性卵巢癌的诊断，治疗和随访, objectType=article, longId=136713, objectId=5971136e13a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5971136e13a9, replyNumber=0, likeNumber=29, createdTime=2018-04-29, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5971136e13a9, moduleTitle=2018 ESMO临床实践指南：非上皮性卵巢癌的诊断，治疗和随访, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5971136e13a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280954, encodeId=f01e1280954d5, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2018 ESMO临床实践指南：癌症患者贫血和铁缺乏的管理, objectType=article, longId=130671, objectId=43cc1306e1c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43cc1306e1c7, replyNumber=0, likeNumber=26, createdTime=2018-02-28, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43cc1306e1c7, moduleTitle=2018 ESMO临床实践指南：癌症患者贫血和铁缺乏的管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43cc1306e1c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280953, encodeId=b7a61280953e1, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO Open：TRICOLORE研究为转移性结直肠癌一线治疗提供新证据, objectType=article, longId=125361, objectId=b37712536193, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b37712536193, replyNumber=0, likeNumber=32, createdTime=2018-01-04, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b37712536193, moduleTitle=ESMO Open：TRICOLORE研究为转移性结直肠癌一线治疗提供新证据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b37712536193)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280952, encodeId=6575128095243, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=【ESMO Asia】FLAURA研究奠定奥希替尼一线标准治疗地位, objectType=article, longId=121278, objectId=c84a1212e86d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c84a1212e86d, replyNumber=0, likeNumber=0, createdTime=2017-11-26, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c84a1212e86d, moduleTitle=【ESMO Asia】FLAURA研究奠定奥希替尼一线标准治疗地位, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c84a1212e86d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280951, encodeId=aecd1280951f6, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=【2017 ESMO ASIA】内外科专家共同讨论转移性肾癌局部治疗, objectType=article, longId=121064, objectId=acf812106476, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acf812106476, replyNumber=0, likeNumber=65, createdTime=2017-11-24, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acf812106476, moduleTitle=【2017 ESMO ASIA】内外科专家共同讨论转移性肾癌局部治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acf812106476)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280950, encodeId=7e9912809501d, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2017 ESMO Asia AXEPT研究结果公布, objectType=article, longId=120916, objectId=607512091624, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=607512091624, replyNumber=0, likeNumber=59, createdTime=2017-11-23, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=607512091624, moduleTitle=2017 ESMO Asia AXEPT研究结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=607512091624)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280949, encodeId=ccac12809490c, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=【ESMO Asia】FLAURA研究：奥希替尼显著延长PFS及ORR, objectType=article, longId=120734, objectId=3f0d120e34d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f0d120e34d1, replyNumber=0, likeNumber=88, createdTime=2017-11-21, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f0d120e34d1, moduleTitle=【ESMO Asia】FLAURA研究：奥希替尼显著延长PFS及ORR, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f0d120e34d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280948, encodeId=65df12809486c, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=【ESMO Asia】PACIFIC研究：Durvalumab显著延长局部晚期NSCLC的PFS, objectType=article, longId=120733, objectId=d89c120e33b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d89c120e33b7, replyNumber=0, likeNumber=65, createdTime=2017-11-21, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d89c120e33b7, moduleTitle=【ESMO Asia】PACIFIC研究：Durvalumab显著延长局部晚期NSCLC的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d89c120e33b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280947, encodeId=358a128094e27, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=【ESMO ASIA 2017】阿昔替尼一线治疗亚洲人群数据发布, objectType=article, longId=120732, objectId=7aba120e32fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7aba120e32fd, replyNumber=0, likeNumber=66, createdTime=2017-11-21, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7aba120e32fd, moduleTitle=【ESMO ASIA 2017】阿昔替尼一线治疗亚洲人群数据发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7aba120e32fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280946, encodeId=a6d9128094606, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=【ESMO Asia】FLAURA研究：奥希替尼显著降低脑转移患者进展和死亡风险, objectType=article, longId=120687, objectId=615212068e26, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=615212068e26, replyNumber=0, likeNumber=56, createdTime=2017-11-21, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=615212068e26, moduleTitle=【ESMO Asia】FLAURA研究：奥希替尼显著降低脑转移患者进展和死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=615212068e26)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280945, encodeId=670c1280945da, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=【ESMO Asia 2017】舒尼替尼的个体化治疗, objectType=article, longId=120685, objectId=11cb12068513, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11cb12068513, replyNumber=0, likeNumber=65, createdTime=2017-11-21, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11cb12068513, moduleTitle=【ESMO Asia 2017】舒尼替尼的个体化治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11cb12068513)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280944, encodeId=271d1280944fc, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=J Clin Oncol：ESMO 氟维司群在晚期乳腺癌内分泌治疗中的新近进展, objectType=article, longId=114053, objectId=4b7d1140536a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b7d1140536a, replyNumber=0, likeNumber=61, createdTime=2017-09-26, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b7d1140536a, moduleTitle=J Clin Oncol：ESMO 氟维司群在晚期乳腺癌内分泌治疗中的新近进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b7d1140536a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280943, encodeId=eb7c12809434a, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO ：朱丽教授解读乳腺癌热点内容, objectType=article, longId=114044, objectId=ad951140442f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad951140442f, replyNumber=0, likeNumber=61, createdTime=2017-09-26, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad951140442f, moduleTitle=ESMO ：朱丽教授解读乳腺癌热点内容, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad951140442f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280942, encodeId=cfef128094250, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO:吴鸣教授：卵巢癌PARPi维持治疗进展, objectType=article, longId=113966, objectId=398e11396633, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=398e11396633, replyNumber=0, likeNumber=97, createdTime=2017-09-25, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=398e11396633, moduleTitle=ESMO:吴鸣教授：卵巢癌PARPi维持治疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=398e11396633)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280941, encodeId=ba5012809415a, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO热点追踪之乳乳腺癌再启征程——PARP抑制剂展风采, objectType=article, longId=112977, objectId=a4831129e7a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4831129e7a8, replyNumber=0, likeNumber=51, createdTime=2017-09-17, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4831129e7a8, moduleTitle=ESMO热点追踪之乳乳腺癌再启征程——PARP抑制剂展风采, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4831129e7a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280940, encodeId=f3ff128094089, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO Open:NSCLC免疫治疗：新治疗、新次序, objectType=article, longId=108026, objectId=beb01080268e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=beb01080268e, replyNumber=0, likeNumber=55, createdTime=2017-08-09, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=beb01080268e, moduleTitle=ESMO Open:NSCLC免疫治疗：新治疗、新次序, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=beb01080268e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280939, encodeId=89361280939f0, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO:远离结肠直肠癌，地中海饮食更适合你！, objectType=article, longId=104532, objectId=cc9310453287, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc9310453287, replyNumber=0, likeNumber=61, createdTime=2017-07-06, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc9310453287, moduleTitle=ESMO:远离结肠直肠癌，地中海饮食更适合你！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc9310453287)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280938, encodeId=8081128093801, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO欢迎2017年世界卫生组织抗癌决议获得通过, objectType=article, longId=101020, objectId=f752101020ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f752101020ff, replyNumber=0, likeNumber=0, createdTime=2017-06-09, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f752101020ff, moduleTitle=ESMO欢迎2017年世界卫生组织抗癌决议获得通过, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f752101020ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280937, encodeId=6eb7128093e93, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO OPEN：无驱动基因的晚期 NSCLC在一线化疗失败后，何去何从, objectType=article, longId=92709, objectId=06fd92e097b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06fd92e097b, replyNumber=0, likeNumber=81, createdTime=2017-03-23, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06fd92e097b, moduleTitle=ESMO OPEN：无驱动基因的晚期 NSCLC在一线化疗失败后，何去何从, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06fd92e097b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280936, encodeId=f02c1280936fb, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=重磅：2016年ESMO全新发布指南 TOP10, objectType=article, longId=85147, objectId=8a1c8514e0c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a1c8514e0c, replyNumber=0, likeNumber=53, createdTime=2016-12-24, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a1c8514e0c, moduleTitle=重磅：2016年ESMO全新发布指南 TOP10, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a1c8514e0c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ESMO

2020-05-29

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2018 ESMO临床实践指南：非上皮性卵巢癌的诊断，治疗和随访

2018-04-29

仁医06 (审核中...)

前往app查看评论内容

#ESMO#

2018 ESMO临床实践指南：癌症患者贫血和铁缺乏的管理

2018-02-28

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO Open：TRICOLORE研究为转移性结直肠癌一线治疗提供新证据

2018-01-04

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

【ESMO Asia】FLAURA研究奠定奥希替尼一线标准治疗地位

2017-11-26

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

【2017 ESMO ASIA】内外科专家共同讨论转移性肾癌局部治疗

2017-11-24

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2017 ESMO Asia AXEPT研究结果公布

2017-11-23

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

【ESMO Asia】FLAURA研究：奥希替尼显著延长PFS及ORR

2017-11-21

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

【ESMO Asia】PACIFIC研究：Durvalumab显著延长局部晚期NSCLC的PFS

2017-11-21

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

【ESMO ASIA 2017】阿昔替尼一线治疗亚洲人群数据发布

2017-11-21

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

【ESMO Asia】FLAURA研究：奥希替尼显著降低脑转移患者进展和死亡风险

2017-11-21

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

【ESMO Asia 2017】舒尼替尼的个体化治疗

2017-11-21

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

J Clin Oncol：ESMO 氟维司群在晚期乳腺癌内分泌治疗中的新近进展

2017-09-26

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO ：朱丽教授解读乳腺癌热点内容

2017-09-26

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO:吴鸣教授：卵巢癌PARPi维持治疗进展

2017-09-25

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO热点追踪之乳乳腺癌再启征程——PARP抑制剂展风采

2017-09-17

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO Open:NSCLC免疫治疗：新治疗、新次序

2017-08-09

hb2008ye (审核中...)

前往app查看评论内容

#ESMO#

ESMO:远离结肠直肠癌，地中海饮食更适合你！

2017-07-06

hb2008ye (审核中...)

前往app查看评论内容

#ESMO#

ESMO欢迎2017年世界卫生组织抗癌决议获得通过

2017-06-09

hb2008ye (审核中...)

前往app查看评论内容

#ESMO#

ESMO OPEN：无驱动基因的晚期 NSCLC在一线化疗失败后，何去何从

2017-03-23

hb2008ye (审核中...)

前往app查看评论内容

#ESMO#

重磅：2016年ESMO全新发布指南 TOP10

2016-12-24

科室
- - 订阅+
  - 更多科室
工具
服务